MYCN is known to be amplified in 16-25% of neuroblastomas, an aberration associated with a poorer prognosis, and it undergoes prognostically relevant copy number gain, and more rarely amplification, in other paediatric tumours including medulloblastoma [24, 25] and rhabdomyosarcoma [26]. This evidence concerns the gene MYCN and rhabdomyosarcoma.